Malignant pleural mesothelioma (MPM) is a thoracic malignancy that is characterized by a very dismal prognosis. Patients with MPM face a large unmet medical need, with almost no therapeutic advances over the last decade. Recently, however, an important step was made in the management of these patients with the registration of immune checkpoint inhibition (ICI) as a new treatment option for treatment-naïve patients with unresectable MPM. Here we summarize the available evidence supporting the use of ICI in MPM. In addition, the article will address remaining issues such as treatment sequencing and optimal first-line treatment selection.